Germany's Evotec has entered into another strategic partnership with a US university as it continues to adopt an open innovation approach to drug discovery.
The latest agreement will see Evotec join forces with Yale University in Connecticut on discovery science for a number of diseases with unmet medical need, including metabolic diseases, disorders of the central nervous system (CNS), immunological diseases and cancer.
To read the original article: Evotec expands open innovation push with Yale deal - PMLiVE
